Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Shares Issued (2021 - 2025)

Krystal Biotech's Shares Issued history spans 5 years, with the latest figure at -$7.0 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 387.15% year-over-year to -$7.0 million; the TTM value through Sep 2025 reached $9.4 million, down 93.67%, while the annual FY2024 figure was $32.4 million, 79.72% down from the prior year.
  • Shares Issued for Q4 2025 was -$7.0 million at Krystal Biotech, down from $3.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $202.1 million in Q4 2021 and bottomed at -$25.9 million in Q4 2022.
  • The 5-year median for Shares Issued is $2.9 million (2024), against an average of $27.7 million.
  • The largest annual shift saw Shares Issued surged 15527.14% in 2022 before it crashed 387.15% in 2025.
  • A 5-year view of Shares Issued shows it stood at $202.1 million in 2021, then plummeted by 112.83% to -$25.9 million in 2022, then surged by 557.43% to $118.6 million in 2023, then crashed by 97.95% to $2.4 million in 2024, then plummeted by 387.15% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Shares Issued are -$7.0 million (Q4 2025), $3.7 million (Q3 2025), and $1.8 million (Q2 2025).